Cerebain Biotech Has Made a Capital Investment in Diabetes Reversal Group, LLC

Rhea-AI Summary

Cerebain Biotech Corp. (OTC: CBBT) announced a capital investment in Diabetes Reversal Group, LLC (DRG), highlighting its confidence in DRG's potential to address the growing Type 2 diabetes market. DRG boasts a patented system that reverses Type 2 diabetes with a proven track record over 13 years, having helped thousands achieve better health and reduce medication reliance. The partnership aims to enhance DRG's reach nationally and internationally, providing natural treatment alternatives to traditional drug therapies. Cerebain is focused on developing innovative medical solutions related to cognitive function.

Positive

• Cerebain made a capital investment in Diabetes Reversal Group, indicating a strategic move in the diabetes treatment market.
• DRG has a patented system that addresses Type 2 diabetes, potentially offering significant market opportunities.
• The partnership allows for expansion into national and international markets.

Negative

• None.

COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announced that it has made a capital investment in Diabetes Reversal Group, LLC.

“Cerebain is happy to announce it has made a capital investment in Diabetes Reversal Group, LLC (DRG). We are confident in the growth potential of DRG due to the size of the diabetes market and the demand for ways to reverse this epidemic disease,” says Eric Clemons, CEO of Cerebain.

DRG has the only patented system in the world that reverses Type 2 Diabetes, and they guarantee results. They have a 13-year track record and have helped thousands of diabetics reverse their disease once and for all and get off their medications.

“We are excited to expand nationally and internationally with our incredible program, so we can help diabetics reverse this disease that causes so many devastating complications,” says Kristine Burke, MD, who is triple board certified and the Chief Medical Officer of DRG.

About Cerebain Biotech Corp.

Cerebain Biotech Corp. is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.

About Diabetes Reversal Group, LLC

Diabetes Reversal Group, LLC was founded to provide a natural diabetes treatment, non-drug approach to helping people with metabolic and nutritional imbalances. These imbalances can lead to many health problems traditionally treated with invasive prescription drug therapy, such as Type 2 Diabetes, Neuropathy and Heart Disease. The Patented program developed by DRG helps Type 2 Diabetes, Neuropathy and Heart Disease by restoring proper metabolic function and nutritional balance. We have seen remarkable results with the improvement or elimination of these conditions, working in conjunction with your primary physician. Visit us at https://diabetesreversalgroup.com.

Forward Looking Statements

This news release contains certain "forward- looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005273/en/

Investors:

Mr. Alan Klitenic

Cerebain Biotech Corp.

888.430.2221

info@cerebain.com

Source: Cerebain Biotech Corp.

FAQ

What is Cerebain Biotech's recent investment related to CBBT?

Cerebain Biotech Corp. has made a capital investment in Diabetes Reversal Group, LLC, aimed at addressing the Type 2 diabetes market.

What is the significance of the investment in Diabetes Reversal Group for CBBT shareholders?

The investment suggests growth potential in the diabetes treatment sector, which could benefit CBBT shareholders if successful.

What does Diabetes Reversal Group's patented system claim to do?

Diabetes Reversal Group's patented system claims to reverse Type 2 diabetes and has a 13-year successful track record.

How might Cerebain's investment in DRG affect its stock performance?

If DRG's program is successful, it could enhance Cerebain's market position and positively impact CBBT's stock performance.